OPPI elects Suresh Pattathil as New President
The term, for a period of two years, is effective from 26th September, 2022
The Organisation of Pharmaceutical Producers of India (OPPI) has elected Suresh Pattathil as its next President. The term, for a period of two years, is effective from 26th September, 2022.
Pattathil, MD and GM, Allergan, takes over from S Sridhar, MD, Pfizer India, who has been with the association since 2021, a statement from OPPI notified.
Speaking on his appointment, Pattathil said in the statement, “……….Health, today, has become a priority for the government, and OPPI, as an association, focussed on research and innovation, is working towards solving some of the most pressing healthcare needs. I look forward to making a difference to patients and the industry as OPPI works with the government to enable healthcare access. I thank the members of OPPI’s Executive Committee who selected me for this role.”
Pattathil, most recently, was the Chief Executive Officer for Ferring Pharma India with responsibility for commercial operations, research and development centre, and setting up a pilot plant and manufacturing facility in Hyderabad. He holds experience in specialty as well as mass therapeutic areas, and in launching global products in India.
Commenting on the development, Vivek Sehgal, Director General, OPPI, also said in the statement, “………I welcome Suresh on-board and am confident that with his expertise, we will be able to achieve many more milestones and remain committed to enhancing OPPI’s leadership in bringing innovative drugs and new therapies for unmet medical needs. He has always been a strong voice for healthcare transformation in the country, and under his able leadership, we will continue to put in efforts to optimise patient outcomes by creating an environment conducive to innovation and growth as well as continue to engage deeply with the government stakeholders.”